Staphylococcus aureus Infections After Elective Cardiothoracic Surgery: Observations From an International Randomized Placebo-Controlled Trial of an Investigational S aureus Vaccine.

dc.contributor.author

Allen, Keith B

dc.contributor.author

Fowler, Vance G

dc.contributor.author

Gammie, James S

dc.contributor.author

Hartzel, Jonathan S

dc.contributor.author

Onorato, Matthew T

dc.contributor.author

DiNubile, Mark J

dc.contributor.author

Sobanjo-Ter Meulen, Ajoke

dc.coverage.spatial

United States

dc.date.accessioned

2017-01-01T20:02:51Z

dc.date.issued

2014-09

dc.description.abstract

BACKGROUND: An unmet need to prevent Staphylococcus aureus (SA) infections after cardiothoracic surgery persists despite current practices. Cost-effective implementation of preventive strategies requires contemporary knowledge about modifiable risk factors. METHODS: From 2007 to 2011, an international, double-blind, randomized placebo-controlled trial of a novel SA vaccine (V710) was conducted in 7664 adults scheduled for median sternotomy at 164 sites. We analyzed SA infections developing up to 360 days postoperatively in 3832 placebo recipients. RESULTS: Coronary artery bypass grafting was performed in 80.8% (3096 of 3832) of placebo recipients. The overall incidence of any postoperative SA infection was 3.1% (120 of 3832). Invasive SA infections (including bacteremia and deep sternal-wound infections) developed in 1.0%. Methicillin-resistant SA (MRSA) accounted for 19% (23 of 120) of SA infections, with 57% (13 of 23) of the MRSA infections occurring in diabetic patients. All-cause mortality was 4.1% (153 of 3712) in patients without SA infection, 7.2% (7 of 97) in methicillin-susceptible SA (MSSA) infections, and 17.3% (4 of 23) in MRSA infections (P < .01). Staphylococcus aureus nasal carriage was detected preoperatively in 18.3% (701 of 3096) patients, including 1.6% colonized with MRSA. Postoperative SA infections occurred in 7.0% (49 of 701) of colonized patients versus 2.3% (71 of 3131) of patients without colonization (relative risk = 3.1 [95% confidence interval, 2.2-4.4]). CONCLUSIONS: In this large international cohort of patients undergoing cardiac surgery and observed prospectively, invasive postoperative SA infections occurred in 1% of adult patients despite modern perioperative management. The attributable mortality rates were 3% for MSSA and 13% for MRSA infections. Preoperative nasal colonization with SA increased the risk of postoperative infection threefold. The utility of strategies to reduce this incidence warrants continued investigation.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/25734141

dc.identifier

ofu071

dc.identifier.uri

https://hdl.handle.net/10161/13307

dc.language

eng

dc.publisher

Oxford University Press (OUP)

dc.relation.ispartof

Open Forum Infect Dis

dc.relation.isversionof

10.1093/ofid/ofu071

dc.subject

Merck V710 vaccine

dc.subject

Staphylococcus aureus

dc.subject

cardiac surgery

dc.subject

postoperative infection

dc.title

Staphylococcus aureus Infections After Elective Cardiothoracic Surgery: Observations From an International Randomized Placebo-Controlled Trial of an Investigational S aureus Vaccine.

dc.type

Journal article

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/25734141

pubs.begin-page

ofu071

pubs.issue

2

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Infectious Diseases

pubs.organisational-group

Molecular Genetics and Microbiology

pubs.organisational-group

School of Medicine

pubs.publication-status

Published online

pubs.volume

1

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Staphylococcus aureus Infections After Elective Cardiothoracic Surgery: Observations From an International Randomized Placebo-Controlled Trial of an Investigational S aureus Vaccine.pdf
Size:
114.78 KB
Format:
Adobe Portable Document Format